We are developing a therapy that reduces the overproduction and secretion of these cytokines. It is designed to work for any condition that induces an overly robust secretion of cytokines.
Our program to treat Long-COVID is designed to reduce the inflammatory response that causes and perpetuates the debilitating symptoms of this illness, while not causing immunosuppression.
The data from our Influenza-Like Illness (ILI) program indicates that our approach reduces the time for symptoms to resolve, regardless if Influenza, COVID, RSV, Rhinovirus, Norovirus, or others are the pathogen. This makes NKT a perfect first-line therapy for ILI because no testing is required, and treatment can begin immediately. In addition, new pathogens cannot become resistant to host targeted therapies and it will work on emerging pathogens that cause cytokine storm, even if they have not yet been characterized.